Trial · NCT00430248
Outcomes17
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Subjects Whose Serum Urate Level is <6.0 Milligrams Per Deciliter (mg/dL) at the Final Visit. | Last Visit on treatment (up to 6 months) | Analysis was performed on intent-to-treat (ITT) subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had baseline serum urate ≥8.0 mg/dL. A subject's baseline value was used in the primary analysis if no postbaseline serum urate level was obtained. | percentage of subjects | NUMBER |
| SECONDARY | Percentage of Renal Impairment Subjects Whose Final Visit Serum Urate Level is <6.0 mg/dl | Last Visit on treatment (up to 6 months) | Analysis was performed on the ITT subjects with mild-to-moderate renal impairment (estimated creatinine clearance of 30 mL/min to 89 mL/min), with a post-baseline serum urate level. | percentage of subjects | NUMBER |
| SECONDARY | Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 2 Visit. | Month 2 | Analysis was performed on the ITT subjects with a serum urate value at Month 2 visit. | percentage of subjects | NUMBER |
| SECONDARY | Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 4 Visit. | Month 4 | Analysis was performed on the ITT subjects with a serum urate value at Month 4 visit. | percentage of subjects | NUMBER |
| SECONDARY | Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 6 Visit. | Month 6 | Analysis was performed on the ITT subjects with a serum urate value at Month 6 visit. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 2 Visit. | Month 2 | Analysis was performed on the ITT subjects with a serum urate value at Month 2 visit | percentage of subjects | NUMBER |
| SECONDARY | Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 4 Visit. | Month 4 | Analysis was performed on the ITT subjects with a serum urate value at Month 4 visit. | percentage of subjects | NUMBER |
| SECONDARY | Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 6 Visit. | Month 6 | Analysis was performed on the ITT subjects with a serum urate value at Month 6 visit. | percentage of subjects | NUMBER |
| SECONDARY | Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Final Visit. | Last Visit on treatment (up to 6 months) | Analysis was performed on the ITT subjects with a post-baseline serum urate value. | percentage of subjects | NUMBER |
| SECONDARY | Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 2 Visit | Month 2 | Analysis was performed on the ITT subjects with a serum urate value at Month 2 visit. | percentage of subjects | NUMBER |
| SECONDARY | Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 4 Visit | Month 4 | Analysis was performed on the ITT subjects with a serum urate value at Month 4 visit. | percentage of subjects | NUMBER |
| SECONDARY | Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 6 Visit | Month 6 | Analysis was performed on the ITT subjects with a serum urate value at Month 6 visit. | percentage of subjects | NUMBER |
| SECONDARY | Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Final Visit | Last Visit on treatment (up to 6 months) | Analysis was performed on the ITT subjects with a post-baseline serum urate value. | percentage of subjects | NUMBER |
| SECONDARY | Mean Percent Change From Baseline in Serum Urate Levels at Month 2 Visit. | Baseline and Month 2 | Analysis was performed on the ITT subjects with a serum urate value at Month 2 visit. | percent change from baseline | MEAN |
| SECONDARY | Mean Percent Change From Baseline in Serum Urate Levels at Month 4 Visit | Baseline and Month 4 | Analysis was performed on the ITT subjects with a serum urate value at Month 4 visit. | percent change from baseline | MEAN |
| SECONDARY | Mean Percent Change From Baseline in Serum Urate Levels at Month 6 Visit. | Baseline and Month 6 | Analysis was performed on the ITT subjects with a serum urate value at Month 6 visit. | percent change from baseline | MEAN |
| SECONDARY | Mean Percent Change From Baseline in Serum Urate Levels at Final Visit. | Baseline and Last Visit on treatment (up to 6 months) | Analysis was performed on the ITT subjects with a post-baseline serum urate value. | percent change from baseline | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00430248/outcomes